Business Model

Selmod is performing the research and clinical development of new anti-infective therapies to the end-of-phase 2 approval.
Investments are done into individual pre-clinical research and clinical development drugs.
A core team of employees will manage, coordinate and validate all out-sourced activities.

Priority pathogens for which new therapies are needed.

Multi-drug resistant Bacteria

Carbapenem resistant Enterobacteriaceae ESBL-producing Enterobacteriaceae Multidrug-resistant Pseudomonas aeruginosa
Carbapenem-resistant Acinetobacter baumannii

Life-threatening Fungi

Drug-resistant Candida spp., including Candida auris
Drug-resistant Aspergillus spp.

Antimicrobial resistance therapies are an emerging market.

Currently we have 750’000 infections p.a. EU/US with resistant bacteria. 40’000 associated deaths p.a. EU/US due to antimicrobial resistance (AMR).
Selmod has innovative drug candidates with proven in-vivo efficacy against WHO priority 1 and 2 life-threatening infections from microorganisms.
Our leading antibiotic drug candidate slm 500 is active against multi-resistant clinical isolates in infection studies.